Adam Fridhammar

Affiliations

The Swedish Institute for Health Economics, Lund, Sweden.

ORCID: http://orcid.org/0000-0003-3715-003X

Publications (7)

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer.

Breast cancer research and treatment

Avec: Ida Skarping , Kristoffer Nilsson , Looket Dihge , Adam Fridhammar , Mattias Ohlsson , Linnea Huss , Pär-Ola Bendahl , Katarina Steen Carlsson , Lisa Rydén

Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Avec: James Altunkaya , Xinyu Li , Amanda Adler , Talitha Feenstra , Adam Fridhammar , Mi Jun Keng , Mark Lamotte , Phil McEwan , Andreas Nilsson , Andrew J Palmer , Jianchao Quan , Harry Smolen , An Tran-Duy , William Valentine , Michael Willis , José Leal , Philip Clarke

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.

PharmacoEconomics - open

Avec: Björn Eliasson , Åsa Ericsson , Adam Fridhammar , Andreas Nilsson , Sofie Persson , Barrie Chubb

The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development.

PharmacoEconomics - open

Avec: Adam Fridhammar , Ulrika Axelsson , Ulf Persson , Anders Bjartell , Carl A K Borrebaeck

MRI-only radiotherapy from an economic perspective: Can new techniques in prostate cancer treatment be cost saving?

Clinical and translational radiation oncology

Avec: Emilia Persson , Niklas Svanberg , Jonas Scherman , Christian Jamtheim Gustafsson , Adam Fridhammar , Frida Hjalte , Sven Bäck , Per Nilsson , Adalsteinn Gunnlaugsson , Lars E Olsson

Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.

PharmacoEconomics

Avec: Michael Willis , Adam Fridhammar , Jens Gundgaard , Andreas Nilsson , Pierre Johansen

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.

Applied health economics and health policy

Avec: Sara Stafford , Peter G Bech , Adam Fridhammar , Nino Miresashvili , Andreas Nilsson , Michael Willis , Aiden Liu

Réseau de co-auteurs

Andreas Nilsson 4 collaborations

Michael Willis 3 collaborations

Ida Skarping 1 collaboration

Kristoffer Nilsson 1 collaboration

Looket Dihge 1 collaboration

Mattias Ohlsson 1 collaboration

Linnea Huss 1 collaboration

Pär-Ola Bendahl 1 collaboration

Katarina Steen Carlsson 1 collaboration

Lisa Rydén 1 collaboration

James Altunkaya 1 collaboration

Xinyu Li 1 collaboration

Amanda Adler 1 collaboration

Talitha Feenstra 1 collaboration

Mi Jun Keng 1 collaboration

Mark Lamotte 1 collaboration

Phil McEwan 1 collaboration

Andrew J Palmer 1 collaboration

Jianchao Quan 1 collaboration

Harry Smolen 1 collaboration

An Tran-Duy 1 collaboration

William Valentine 1 collaboration

José Leal 1 collaboration

Philip Clarke 1 collaboration

Björn Eliasson 1 collaboration

Åsa Ericsson 1 collaboration

Sofie Persson 1 collaboration

Barrie Chubb 1 collaboration

Ulrika Axelsson 1 collaboration

Ulf Persson 1 collaboration

Anders Bjartell 1 collaboration

Carl A K Borrebaeck 1 collaboration

Emilia Persson 1 collaboration

Niklas Svanberg 1 collaboration

Jonas Scherman 1 collaboration

Christian Jamtheim Gustafsson 1 collaboration

Frida Hjalte 1 collaboration

Sven Bäck 1 collaboration

Per Nilsson 1 collaboration

Adalsteinn Gunnlaugsson 1 collaboration

Lars E Olsson 1 collaboration

Jens Gundgaard 1 collaboration

Pierre Johansen 1 collaboration

Sara Stafford 1 collaboration

Peter G Bech 1 collaboration

Nino Miresashvili 1 collaboration

Aiden Liu 1 collaboration